BioSyent to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023 09:15 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, April 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co....
BioSyent Announces Grant of Restricted Share Units
March 31, 2023 17:42 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 72,020...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2022
March 21, 2023 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 21, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2022. Key...
BioSyent Schedules Q4 and Full Year 2022 Earnings Release for March 21, 2023
March 09, 2023 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent annonce le lancement du nouveau FeraMAX(MD) Pd Entretien 45
March 07, 2023 16:01 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 07 mars 2023 (GLOBE NEWSWIRE) -- À la veille de la Journée internationale des femmes, BioSyent Inc. (« BioSyent », « la Société », « Bourse de croissance TSX » : RX) célèbre le...
BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45
March 07, 2023 16:01 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of...
BioSyent Declares First Quarter 2023 Dividend
February 01, 2023 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
December 14, 2022 16:50 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an...
BioSyent Announces Renewal of Normal Course Issuer Bid
December 13, 2022 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Releases Q3 and YTD 2022 Financial Results
November 16, 2022 19:07 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022. Key...